<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760396</url>
  </required_header>
  <id_info>
    <org_study_id>CAT002</org_study_id>
    <nct_id>NCT00760396</nct_id>
  </id_info>
  <brief_title>Multiple-Dose Study of VGX-1027 in Healthy Subjects</brief_title>
  <official_title>A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VGX Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VGX Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability and&#xD;
      pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects&#xD;
      administered for 5 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate:&#xD;
&#xD;
        -  The safety and tolerability of multiple oral doses of VGX 1027 in the range of 40 to&#xD;
           400mg.&#xD;
&#xD;
        -  The pharmacokinetics of VGX 1027 in healthy subjects following the first oral dose (Day&#xD;
           1) and at steady state (Day 5).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as determined by vital signs, ECGs, clinical laboratory evaluations and AE reporting.</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg QD dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg QD dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg QD dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg BID dose group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VGX-1027</intervention_name>
    <description>Subjects will</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent.&#xD;
&#xD;
          -  Healty subjects as determined by no clinically significant deviation from normal as&#xD;
             judged by the investigator in medical history, physical examination, ECGs and clinical&#xD;
             laboratory evaluations.&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 30kg/m2 Â±0.5kg/m2 inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are of childbearing potential.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Women with a positive pregnancy test on enrollment or prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Male subjects who are unwilling to agree to practice barrier contraception during&#xD;
             study participation and 3 months following dosing.&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Current or recent (within 3 months) gastrointestinal disease that may impact the&#xD;
             absorption of the drug.&#xD;
&#xD;
          -  Any major surgery within 4 weeks of enrollment.&#xD;
&#xD;
          -  Donation of blood or plasma to a blood bank or in a clinical study (except a screening&#xD;
             visit) within 4 weeks of enrollment.&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of enrollment.&#xD;
&#xD;
          -  Inability to tolerate oral medication.&#xD;
&#xD;
          -  Inability to be venipunctured and/or tolerate venous access.&#xD;
&#xD;
          -  Recent (within 6 months) drug or alcohol abuse.&#xD;
&#xD;
          -  History of bleeding disorder.&#xD;
&#xD;
          -  History of head trauma or seizures.&#xD;
&#xD;
          -  Any other sound medical, psychiatric and/or social reason as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             vital signs, physical examination, ECG, or clinical laboratory determination.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse&#xD;
&#xD;
          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, HIV 1/2&#xD;
             antibody&#xD;
&#xD;
          -  History of any significant drug allergy&#xD;
&#xD;
          -  Exposure to any investigational druge within 4 weeks prior to enrollment or greater&#xD;
             than 4 weeks for investigational drugs that may have a longer half life.&#xD;
&#xD;
          -  Use of any prescription drugs, over the counter acid controllers within 4 weeks prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Use of any other drugs, including over the counter vitamins, medications and/or herbal&#xD;
             preparations within 2 weeks prior to enrollment&#xD;
&#xD;
          -  Use of oral, injectable or implantable hormonal contraceptive agents within three&#xD;
             months prior to enrollment&#xD;
&#xD;
          -  Use of alcohol containing beverages within 1 week prior to enrollment&#xD;
&#xD;
          -  Use of grapefruit containing products within 1 week prior to enrollment&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan A Bart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>C. Jo White, MD</name_title>
    <organization>VGX Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

